Alexander Porte is a registered patent agent and has more than 20 years of pharmaceuticals experience in both medical and synthetic chemistry. He has worked on intellectual property litigation, ANDA, and patent prosecution matters in the pharmaceuticals industry as well as for non-pharmaceutical inventions.
Prior to his role as a patent agent in the legal industry, Alexander served as a Principal Scientist at Pfizer.
Co-author, "Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications," Journal of Medicinal Chemistry, 2014
Co-author, “Recent Advances in the Identification of γ-Secretase Inhibitors to Clinically Test the Αβ Oligomer Hypothesis of Alzheimer’s Disease,” Journal of Medicinal Chemistry, 2009
Co-author, “Discovery of Begacestat, a Notch-1-Sparing γ -Secretase Inhibitor for the Treatment of Alzheimer's Disease,” Journal of Medicinal Chemistry, 2008
Texas A&M University (Ph.D., organic chemistry, 1998)
Calvin College (B.S., chemistry, 1992)